Division of Cardiovascular Medicine, University of Toledo, Toledo, Ohio.
Division of Cardiovascular Medicine, University of Toledo, Toledo, Ohio.
Am J Cardiol. 2023 Jul 1;198:108-112. doi: 10.1016/j.amjcard.2023.04.010. Epub 2023 May 13.
The timing of when to perform ventricular tachycardia (VT) ablation while receiving an implantable cardioverter defibrillator (ICD) during the same hospitalization has not been explored. This study aimed to investigate the use and outcomes of VT catheter ablation in patients with sustained VT receiving ICD in the same hospital stay. The Nationwide Readmission Database 2016 to 2019 was queried for all hospitalizations with a primary diagnosis of VT with subsequent ICD during the same admission. Hospitalizations were later stratified according to whether a VT ablation was performed. All catheter ablation of VT were performed before ICD implantation. The outcomes of interest were in-hospital mortality and 90-day readmission. A total of 29,385 VT hospitalizations were included. VT ablation was performed with subsequent ICD placement in 2,255 (7.6%), whereas 27,130 (92.3%) received an ICD only. No differences were found regarding in-hospital mortality (adjusted odds ratio [aOR] 0.83, 95% confidence interval [CI] 0.35 to 1.9, p = 0.67) and all-cause 90-day readmission rate (aOR 1.1, 95% CI 0.95 to 1.3, p = 0.16). An increase in readmission because of recurrent VT was noted in the VT ablation group (aOR 1.53, 8% vs 5% CI 1.2 to 1.9, p <0.01); the VT ablation group encompassed a higher number of patients with heart failure with reduced ejection fraction (p <0.01), cardiogenic shock (p <0.01), and mechanical circulatory support use (p <0.01). In conclusion, the use of VT ablation in patients admitted with sustained VT is low and reserved for higher risk patients with significant co-morbidities. Despite the higher risk profile of VT ablation cohort, no differences were found in the short-term mortality and readmission rate between the groups.
在同一住院期间接受植入式心律转复除颤器 (ICD) 治疗时,何时进行室性心动过速 (VT) 消融术的时机尚未得到探索。本研究旨在调查在同一住院期间因持续性 VT 接受 ICD 治疗的患者中,VT 导管消融术的使用情况和结果。从 2016 年至 2019 年,使用国家再入院数据库 (Nationwide Readmission Database) 调查所有因 VT 初次诊断并在同一住院期间随后接受 ICD 治疗的住院患者。根据是否进行 VT 消融术对住院情况进行分层。所有 VT 的导管消融术均在 ICD 植入前进行。感兴趣的结果是住院期间死亡率和 90 天再入院率。共纳入 29385 例 VT 住院患者。在 2255 例患者中进行了 VT 消融术并随后放置 ICD(7.6%),而 27130 例患者仅接受了 ICD(92.3%)。在住院期间死亡率方面无差异(调整后比值比 [aOR] 0.83,95%置信区间 [CI] 0.35 至 1.9,p=0.67)和全因 90 天再入院率(aOR 1.1,95% CI 0.95 至 1.3,p=0.16)。在 VT 消融组中,因复发性 VT 导致的再入院率增加(aOR 1.53,8%比 5% CI 1.2 至 1.9,p<0.01);VT 消融组包含更多患有射血分数降低性心力衰竭(p<0.01)、心源性休克(p<0.01)和机械循环支持治疗(p<0.01)的患者。总之,在因持续性 VT 入院的患者中,VT 消融术的使用率较低,仅用于伴有严重合并症的高危患者。尽管 VT 消融组的风险状况较高,但两组间的短期死亡率和再入院率无差异。